1
|
Goujon C, Viguier M, Staumont-Sallé D, Bernier C, Guillet G, Lahfa M, Ferrier Le Bouedec MC, Cambazard F, Bottigioli D, Grande S, Dahel K, Bérard F, Rabilloud M, Mercier C, Nicolas JF. Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial. J Allergy Clin Immunol Pract 2017; 6:562-569.e3. [PMID: 28967549 DOI: 10.1016/j.jaip.2017.07.007] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Revised: 06/14/2017] [Accepted: 07/12/2017] [Indexed: 10/18/2022]
Abstract
BACKGROUND Methotrexate is currently used to treat atopic dermatitis but has never been assessed versus cyclosporine in adults. OBJECTIVE This study evaluated the efficacy and safety of methotrexate versus cyclosporine in patients with moderate-to-severe atopic dermatitis. METHODS Patients were randomized to receive either oral methotrexate (15 mg/wk) or cyclosporine (2.5 mg/kg/d) for 8 weeks. The primary end point was a patient achieving 50% improvement in the SCORing Atopic Dermatitis index (SCORAD 50) at week 8. When the primary end point was not achieved, methotrexate was increased to 25 mg and cyclosporine to 5 mg during the next 16 weeks. The secondary end points were a patient achieving a 50% reduction in the Eczema Area Severity Intensity index (EASI 50) and SCORAD 50 at each visit (ClinicalTrials.gov no. NCT00809172). RESULTS A total of 97 patients received methotrexate 15 mg (n = 50) or cyclosporine 2.5 mg (n = 47). Regarding the primary end point at week 8, methotrexate was inferior to cyclosporine because the proportion of patients with SCORAD 50 was 8% (4 of 50) in the methotrexate arm versus 42% (18 of 43) in the cyclosporine arm. The difference in percentages for the 2 treatment groups (2-sided 90% CI) was -34% (-48% to -20%). At week 8, methotrexate and cyclosporine dosages were increased in 56% and 49% of the patients, respectively. Regarding EASI 50, the noninferiority end point was reached at week 20 in 92% (22 of 24) of patients in the methotrexate arm and 87% (26 of 30) of patients in the cyclosporine arm. The treatment-related adverse events were more frequent with cyclosporine (P < .0001). CONCLUSIONS Methotrexate 15 mg/wk was inferior to cyclosporine 2.5 mg/kg/d at week 8. Increasing the doses of methotrexate to 25 mg/wk induced a significant improvement versus cyclosporine at week 20.
Collapse
Affiliation(s)
- Catherine Goujon
- Department of Allergology and Immunology, Clinical Research Unit, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
| | - Manuelle Viguier
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris VII Denis Diderot University, Paris, France
| | - Delphine Staumont-Sallé
- Department of Dermatology, Lille University Medical Centre, Claude Huriez Hospital, Lille, France
| | - Claire Bernier
- Department of Dermatology, Centre Hospitalier, Nantes, France
| | - Gérard Guillet
- Department of Dermatology, Centre Hospitalier, Poitiers and EA 4331 Tissus épithéliaux et cytokines, Université de Poitiers, Poitiers, France
| | - Morad Lahfa
- Department of Dermatology, Centre Hospitalier, Toulouse, France
| | | | - Frédéric Cambazard
- Department of Dermatology, Centre Hospitalier, Université de Saint-Etienne, Saint-Etienne, France
| | - David Bottigioli
- Clinical Research Unit, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - Sophie Grande
- Department of Allergology and Immunology, Clinical Research Unit, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - Karima Dahel
- Clinical Research Unit, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - Frédéric Bérard
- Department of Allergology and Immunology, Clinical Research Unit, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, Université Lyon 1, France
| | - Muriel Rabilloud
- Hospices Civils de Lyon, Service de Biostatistique et Bioinformatique, Lyon, France and CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne, France
| | - Catherine Mercier
- Hospices Civils de Lyon, Service de Biostatistique et Bioinformatique, Lyon, France and CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne, France
| | - Jean-François Nicolas
- Department of Allergology and Immunology, Clinical Research Unit, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, Université Lyon 1, France; Université Lyon 1, Centre International de Recherche en Infectiologie, Inserm U1111, Lyon, France
| |
Collapse
|
2
|
Goujon C, Viguier M, Staumont D, Bernier C, Lahfa M, Ferrier MC, Cambazard F, Grande S, Dahel K, Bottigioli D, Berard F, Nicolas JF. Efficacité du méthotrexate (MTX) versus ciclosporine (Cy) dans la dermatite atopique (DA) modérée à sévère de l’adulte. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
6
|
Etchart N, Hennino A, Friede M, Dahel K, Dupouy M, Goujon-Henry C, Nicolas JF, Kaiserlian D. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine 2007; 25:6891-9. [PMID: 17764789 DOI: 10.1016/j.vaccine.2007.07.014] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2006] [Revised: 05/23/2007] [Accepted: 07/10/2007] [Indexed: 10/23/2022]
Abstract
Transcutaneous immunisation (TCI) using a skin patch is a non-invasive vaccination route relevant to mass vaccination against infectious diseases. This phase I/II clinical study, documents that TCI of human adult volunteers with the live-attenuated measles vaccine ROUVAX((R)) is safe and poorly reactogenic. It promotes induction of measles-specific salivary IgA and a tendency to increased frequency of MV-specific IFNgamma-producing T cells. However, in contrast to the subcutaneous route, TCI failed to evoke neutralising MV-specific serum antibodies. Thus, alternative delivery methods and/or devices providing optimal uptake by skin DC should be considered for live-attenuated virus vaccines, such as the measles vaccine.
Collapse
Affiliation(s)
- Nathalie Etchart
- INSERM U404, Lyon F-69007, France; Université Lyon 1, Lyon F-69003, France; IFR128, Lyon F-69007, France
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Laurent A, Mistretta F, Bottigioli D, Dahel K, Goujon C, Nicolas JF, Hennino A, Laurent PE. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 2007; 25:6423-30. [PMID: 17640778 DOI: 10.1016/j.vaccine.2007.05.046] [Citation(s) in RCA: 141] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2006] [Revised: 04/12/2007] [Accepted: 05/13/2007] [Indexed: 02/07/2023]
Abstract
Skin thickness (epidermis-dermis) across the deltoid, suprascapular, waist and thigh as possible body sites for a new microdelivery system for intradermal (id) inoculation were evaluated using 20 MHz ultrasound echography in 205 women and 137 men aged 18-70 years, in three ethnic groups: Caucasian, Asian and Black. Mean skin thickness was 2.54 mm at the suprascapular, 2.02 mm at the deltoid, 1.91 mm at the waist and 1.55 mm at the thigh. A 1.5 mm microneedle length inserted perpendicularly to the skin surface would ensure the administration of the antigen into the dermal layer, irrespectively of subject gender, age, ethnicity and BMI. The deltoid, suprascapular and waist are the most appropriate body sites.
Collapse
Affiliation(s)
- Aurélie Laurent
- Palliative Care Unit, Centre Hospitalier Lyon Sud, 69310 Pierre Bénite, France.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Guéniche A, Hennino A, Goujon C, Dahel K, Bastien P, Martin R, Jourdain R, Breton L. Improvement of atopic dermatitis skin symptoms by Vitreoscilla filiformis bacterial extract. Eur J Dermatol 2006; 16:380-4. [PMID: 16935794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/09/2006] [Indexed: 05/11/2023]
Abstract
Atopic dermatitis (AD) is a chronically relapsing inflammatory skin disease. The first line treatment of AD relies on the daily use of emollients to restore the skin barrier impairment associated with the disease. Vitreoscilla filiformis (V.f.) is a non photosynthetic bacterium and extracts of V.f. are endowed with properties which balance cutaneous immune-homeostasis. The aim of our study was to investigate the efficacy and safety of a 5% V.f. extract-containing ointment on mild to moderate AD in a randomised, double-blind, vehicle-controlled trial. Thirteen patients applied the treatment and the vehicle on symmetrical AD lesions (left versus right side of the body) twice daily for 4 weeks. The assessment of AD severity was done at each visit (Day 0, Day 14 and Day 28) using the modified eczema area and severity index (mEASI). Treatment with the ointment containing 5% V.f. extract significantly improved the AD skin symptoms. Beneficial effects were observed after two weeks of treatment and increased thereafter. These results suggest that V.f. extract could be favourably added to AD skin care emollients formulated for AD.
Collapse
|
9
|
Goujon C, Bérard F, Dahel K, Guillot I, Hennino A, Nosbaum A, Saad N, Nicolas JF. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006; 16:155-8. [PMID: 16581567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/18/2005] [Indexed: 05/08/2023]
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease mediated by allergen-specific T cells which are recruited and activated in lesional skin. Methotrexate (MTX) is an old systemic agent used at low dosage for the treatment of psoriasis, another T cell-mediated skin disorder. Since MTX has been shown to improve the clinical symptoms of eczema in a model of antigen-specific dermatitis in mice, we postulated that it could be an effective treatment of AD. In the present open retrospective study, we report our results on the treatment of moderate to severe AD by MTX. Twenty patients (17 to 68-years-old) with low responses to routine therapies were treated (three months to 2 1/2 years) with a weekly dose of MTX ranging from 7.5 to 25 mg. The evaluation was made on physician's global assessment after 3 months of MTX use, and showed that 75% (15/20) of patients improved after 3 months of MTX use, among which 13/20 with an improvement>70%. The beginning of improvement was observed between the fourth and the eighth week after MTX was initiated. Tolerance was good. However, nausea and increase of liver enzymes were observed in 5 patients and required discontinuation of MTX in 2 patients. In conclusion, MTX seems to be an effective and safe treatment of AD. Placebo-controlled clinical trials are needed to confirm our observations and to define more precisely the effectiveness and safety of MTX in adult AD.
Collapse
Affiliation(s)
- Catherine Goujon
- Allergology and Clinical Immunology Department, URCI-LS 36 768 (Unité Recherche Clinique Immunologie- Lyon Sud), Pierre-Benite, and INSERM U 503, IFR 128 Biosciences Lyon-Gerland, France.
| | | | | | | | | | | | | | | |
Collapse
|